WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company, has announced the approval of new compensation terms for a recently hired employee. On June 2, 2025, the company's independent Compensation Committee granted non-qualified stock options to purchase 23,400 shares of common stock as part of an inducement package, following Nasdaq Listing Rule 5635(c)(4). These stock options, set at a price equal to the stock's closing value on the grant date, will vest over four years. The plan stipulates that 25% of the shares will vest after one year of employment, with the remainder vesting in equal monthly installments over the subsequent three years, contingent on continued employment with the company. These terms are outside Viridian's 2016 Equity Incentive Plan but adhere to its conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.